سعر كواتي-ديفي اي 500 وحدة فيال 5 مل 2022

Koate-DVI 500 IU (human plasma-derived antihemophilic factor VIII), single-use vial with 5 ml diluent, for intravenous injection; made by Grifols (USA) and listed in Egypt under Biolinx Medical. Used for bleeding control and prevention in haemophilia A.

• Control and prevention of bleeding episodes, and peri-operative use for emergency and elective surgery, in haemophilia A (hereditary factor VIII deficiency). Not indicated for von Willebrand disease.Population: Patients with haemophilia ADailyMed (U.S. National Library of Medicine)

• Most common in the clinical trial (5% or more): nervousness, headache, abdominal pain, nausea, paraesthesia and blurred vision. Post-marketing: factor VIII inhibition, haemolytic anaemia, hypersensitivity/anaphylaxis, rash, pruritus.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Previous hypersensitivity reactions, including anaphylaxis, to the product or its components.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity reactions including anaphylaxis are possible (angioedema, chest tightness, hypotension, rash, wheezing, dyspnoea); stop immediately and give emergency treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Neutralising antibodies (inhibitors) to factor VIII may develop; suspect them if expected factor levels are not reached or bleeding is not controlled.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Contains blood-group isoagglutinins: large or frequent doses in blood groups A, B or AB may cause intravascular haemolysis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• No data on use in pregnant women and no animal reproduction studies; give to a pregnant woman only if clearly needed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk or effects on the breastfed infant; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Human coagulation factor VIII: Temporarily replaces the missing clotting factor VIII needed for effective haemostasis (US label 12.1).